Strides in STXBP1 Research: March
What was new in March of 2026
Multidisciplinary clinics (MDCs) bring together many different specialists so families dealing with rare epilepsies can get coordinated, whole‑person care in one place. The Rare Epilepsy Network (REN) together with representative from several PAGs, including the STXBP1 Foundation, and physicians published the findings from a workshop and surveys that focused on MDCs. The findings show that caregivers and clinicians overwhelmingly value these clinics because they provide expert guidance, better management of complex medical needs, and access to research opportunities that are hard to find elsewhere. Families report that MDCs reduce stress and often lead to new insights or diagnoses, while clinicians see them as essential for improving care and advancing science. However, both groups face real barriers—families struggle with long travel, high costs, and insurance hurdles, while clinicians cite limited funding, space, and institutional support. The authors argue that expanding MDCs, improving access (including through telehealth), sharing expertise across centers, and tracking standardized measures of success could transform care and research for people living with rare epilepsies.
The biotech company Biogen published a study on the STXBP1 gene replacement therapy they have been working on. The study focused on how much replacement is needed to actually improve symptoms. Using mice that model the human condition, they delivered an AAV-based gene therapy shortly after birth and found that the treatment reduced seizure‑like brain activity, improved movement, and partially improved learning. By carefully measuring how many neurons took up the therapy, they discovered a “therapeutic threshold”: at least about 44% of cortical neurons must receive the gene for meaningful benefit. The therapy’s effects lasted at least a year. The team also developed ways to measure STXBP1 and related proteins in cerebrospinal fluid, which could help track whether the treatment is working in future human trials. Overall, the work lays out a roadmap for dosing, measuring, and evaluating STXBP1 gene therapy as it moves toward clinical use.
Scientists from Amsterdam and Copenhagen published a study to help explain why people with mutations in the same gene, such as STXBP1, can have very different symptoms. They took mice with mutations in Stxbp1 and mice with mutations in Snap25, both of which are involved in synaptic vesicle release, and bred them to obtain mice that contained both mutations. They then performed many experiments comparing normal mice, Stxbp1 mice, Snap25 mice, and Stxbp1/Snap25 mice (double mutation mice). They found that mice that only had a single mutation, either Stxbp1 or Snap25 tended to have consistent symptoms, with the Stxbp1 mice generally having more severe symptoms. Double mutant mice, on the other hand, were unpredictable: some mice had severe, even fatal seizures, while others showed mild symptoms. The team concluded that this variability is due to the way that the two genes interact in a non-linear, multiplicative way, meaning that their combined effects amplify each other unpredictably rather than simply adding up. This may explain why human patients with STXBP1 mutations have very different symptoms – this may be due to the interaction of other genes having a multiplicative effect with the STXBP1 gene.
Chinese researchers generated an Stxbp1 mouse model with an R406H mutation; the R406H variant is one of the most common variants known in the STXBP1 population. When the mice were tested for behavioral problems, they found that the mutant mice showed anxiety, movement problems, and difficulties with learning and memory—similar to what has been observed in other Stxbp1 mouse models. They also found unusually high activity in glial cells—the brain’s support and immune cells—and fewer newly formed neurons in the hippocampus, a region important for memory. Together, these changes suggest that the mutation not only disrupts brain communication but may trigger inflammation that could impair synapse formation.
Italian physicians and researchers examined the medical records and EEGs of 277 children with genetic epilepsies to see if they could associate any particular gene mutations with clinical outcome or EEG patterns. The 277 children together represented 46 different genetic epilepsies including 12 children with STXBP1. Overall, they found that babies with seizures starting in the neonatal period (birth to 28 days) were more likely to develop movement disorders, severe neurodevelopmental delay and intellectual disability, and had a higher rate of drug resistance. Children with STXBP1 were unique in having a strong association with infantile spasms, specific EEG patterns (burst suppression, hypsarrhythmia, paroxysmal), and focal/multifocal epileptiform abnormalities. Other unique clinical and EEG associations were made to other genes. The results suggest that early EEG and clinical data may support early clinical management choices and counseling of families before a genetic diagnosis can be made.
Japanese physicians published a case report describing a baby who initially had focal seizures and later developed epileptic spasms after treatment with ACTH, a hormone therapy often used for infantile spasms. Genetic testing revealed a mutation in the STXBP1 gene. The child’s seizures temporarily improved with ACTH but relapsed shortly after treatment ended. The article emphasizes that children with STXBP1 mutations often have both focal seizures and spasms early in life, and that early genetic diagnosis is crucial for guiding treatment decisions and preparing families for possible relapses. It also suggests that long-term monitoring and personalized care strategies are essential for these patients.
A Polish group examined 87 pediatric patients with unexplained pediatric-onset epilepsy, whom they suspected may have a genetic cause. Using a combination of whole genome sequencing and epilepsy gene panels, the team found a total of 88 pathogenic or likely pathogenic variants in 48 epilepsy-related genes, including 4 patients with pathogenic variants in STXBP1.
